Zampi, Joseph P.

Mark D. McBriar is a technology specialist in the firm’s Intellectual Property Department. He joined the firm in 2010.

Practice

Dr. McBriar focuses his practice on drafting and prosecuting patent applications, due diligence evaluations and litigation support, including Hatch-Waxman litigation. His primary areas of focus are pharmaceutical and life sciences including pharmaceutical compounds, methods of treatment and organic chemistry.

Past Experience

Prior to joining WilmerHale, Mark spent two years as a scientific advisor at another law firm in New York. There, he drafted and prosecuted US patent applications, and directed foreign patent prosecution relating to various pharmaceutical and biotechnology matters. Mark also conducted freedom to operate, invalidity, non-infringement, and patentability studies for clients, as well as due diligence portfolio evaluations. Within the pharmaceuticals and biotechnology area, Mark focused on small molecule anti-tumor, cardiovascular and central nervous system pharmaceuticals, radiolabeled imaging agents, and veterinary and agricultural pesticides. He also handled IP matters related to innovations in the fields of organic chemistry, including small molecule discovery scale and process scale synthesis, and medical devices, including cardiovascular valve repair devices and stents.

Previously, Dr. McBriar was with CV/CNS Discovery Chemical Research at the Schering-Plough Research Institute as an Associate Principal Scientist (2002–2008) and, before that, as a Senior Research Scientist (1999–2002). There, he designed, synthesized and optimized central nervous system preclinical drug candidates for Alzheimer’s and anti-obesity therapeutics.

From 1992 to 1994, prior to obtaining his MS and Ph.D. in organic chemistry, Dr. McBriar worked as an assistant scientist within Cardiovascular Discovery Research at Rhone-Poulenc Rorer, where he synthesized peptidomimetics and non-peptide enzyme platelet aggregation inhibitors for cardiovascular therapies.

Professional Activities

Dr. McBriar is admitted to practice before the United States Patent and Trademark Office. He is a member of the American Intellectual Property Law Association and the American Chemical Society. From 2005 to 2007, he served as a manuscript reviewer for the Journal of Medicinal Chemistry and Bioorganic and Medicinal Chemistry Letters. While with Schering-Plough, Dr. McBriar also served in the Schering-Plough Research Institute School Outreach Program, providing hands-on laboratory instruction for elementary and middle-school students. From 1997 to 2003, Dr. McBriar was a test item writer with the American Institutes for Research.

Selected Journal Publications and Patents

McBriar, M. D.; Clader, J. W.; Del Vecchio, R. A.; Greenlee, W. J.; Hyde, L.; Nomeir, A.; Parker, E. M.; Pissarnitski, D. A.; Song, L.; Zhang, L.; Zhao, Z. “Discovery of Amide and Heteroaryl Isosteres as Carbamate Replacements in a Series of Orally Active Gamma-Secretase Inhibitors” Bioorg. Med. Chem. Lett., 2008, 18, 215.

McBriar, M. D. “Melanin Concentrating Hormone Receptor Antagonists as Antiobesity Agents: From M2 to MCHR-1” Curr. Top. Med. Chem. 2007, 7, 1440.

McBriar, M. D.; Guzik, H.; Shapiro, S.; Xu, R.; Paruchova, J.; Clader, J. W.; O’Neill, K.; Hawes, B.; Sorota, S.; Margulis, M.; Tucker, K.; Weston, D. J.; Cox, K. “Bicyclo[3.1.0]hexyl Urea Melanin Concentrating Hormone (MCH) Receptor-1 Antagonists: Impacting hERG Liability via Aryl Modifications” Bioorg. Med. Chem. Lett. 2006, 16, 4262.

Kowalski, T. J.; Spar, B. D.; Weig, B.; Farley, C.; Cook, J.; Ghibaudi, L.; Fried, S.; O’Neill, K.; Del Vecchio, R. A.; McBriar, M. D.; Guzik, H.; Clader, J.; Hawes, B. E.; Hwa, J. “Effects of a Selective Melanin-Concentrating Hormone 1 Receptor Antagonist on Food Intake and Energy Homeostasis in Diet-Induced Obese Mice” Eur. J. Pharm. 2006, 535, 182.

McBriar, M. D.; Guzik, H.; Shapiro, S.; Paruchova, J.; Xu, R.; Palani, A.; Clader, J. W.; Cox, K.; Greenlee, W. J.; Hawes, B. E.; Kowalski, T. J.; O’Neill, K.; Spar, B. D.; Weig, B.; Weston, D. J.; Ferley, C.; Cook, J. “Discovery of Orally Efficacious Melanin Concentrating Hormone Receptor-1 Antagonists as Antiobesity Agents. Synthesis, SAR and Biological Evaluation of Bicyclo[3.1.0]hexyl Ureas” J. Med. Chem. 2006, 49, 2294.

Smith, A. B., III; Lin, Q.; Doughty, V.; Zhuang, L.; McBriar, M. D.; Kerns, J.; Brook, C.; Murase, N.; Nakayama, K. "The Spongistatins: Architecturally Complex Natural Products. Part Two: Synthesis of the C(29-51) Subunit, Fragment Assembly and Final Elaboration to (+)- Spongistatin 2" Angew. Chem. Int. Ed. Engl. 2001, 40, 196.

Palani, A.; Qin, J.; Zhu, Z.; Aslanian, R. G.; McBriar, M. D. “Gamma secretase modulators” WO 09/020579.Zhu, Z.; Greenlee, W. J.; Sun, Z.; Gallo, G.; Asberom, T.; Huang, X.; Zhu, X.; McBriar, M. D.; Pissarnitski, D. A.; Zhao, Z.; Xu, R.; Li, H.; Palani, A.; Mazzola, R. D.; Clader, J. W.; Josien, H. B.; Qin, J. “Gamma secretase modulators” WO 08/137139.

Asberom, T.; Bara, T.; Bennett, C. E.; Burnett, D. A.; Caplen, M. A.; Clader, J. W.; Cole, D. J.; Domalski, M. S.; Josien, H. B.; Knutson, C. E.; Li, H.; McBriar, M. D.; Pissarnitski, D. A.; Qiang, L.; Rajagopalan, M.; Sasikumar, T. K.; Su, J.; Tang, H.; Wu, W.-L.; Xu, R.; Zhao, Z. “Preparation of benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors” USSN 11/654,821.

Clader, J. W.; Palani, A.; Xu, R.; McBriar, M. D. ; Su, J.; Tang, H. “MCH antagonists for the treatment of obesity” U.S. Patent 7,348,328.